Background The T-cell inhibitory molecule PD-L1 (B7-H1, CD274) is expressed on tumor
cells of a subset of breast cancer patients. However, the mechanism that regulates PD-L1 …

Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and
tumor cells in breast cancer has been reported, but the relationships between PD-L1 …

Abstract Introduction B7-H1 (PD-L1, CD274) is a T cell inhibitory molecule expressed in
many types of cancer, leading to immune escape of tumor cells. Indeed, in previous reports …

Abstract The PD-L1 (CD274) immune-checkpoint ligand is often upregulated in cancers to
inhibit T cells and elicit immunosuppression. Independent of this activity, PD-L1 has recently …

Purpose To systematically review the literature on the expression of PD-L1 in primary BC,
variation of expression between subtypes and effect on overall survival (OS), disease-free …

The T-cell inhibitory molecule PD-L1 is expressed on a fraction of breast cancer cells. The
distribution of PD-L1 on the different subpopulations of breast cancer cells is not well …

Background To investigate the role of PD-L1 expression in tumor recurrence and metastasis
in Chinese patients with breast cancer. Methods Suitable tissue samples were available …

Purpose: Conflicting data have been reported on the prognostic value of PD-L1 protein and
gene expression in breast cancer. Experimental Design: Medline, Embase, Cochrane …

Regulatory T cells (Tregs), a key mediator in regulating anti-tumor immune suppression,
tumor immune escape, metastasis and relapse, are considered an important therapeutic …

Programmed cell death 1 ligand 1 (PD‐L1) is a promising therapeutic target for cancer
immunotherapy. However, the correlation between PD‐L1 and breast cancer survival …